Trial Profile
Phase III Trial On Concurrent And Adjuvant Temozolomide Chemotherapy In Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. (RTOG 0834)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Anaplastic astrocytoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- Acronyms CATNON
- 30 Aug 2023 Planned End Date changed from 1 Dec 2025 to 1 Dec 2029.
- 09 May 2022 Planned End Date changed from 1 Jan 2024 to 1 Dec 2025.
- 09 May 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Dec 2025.